# Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

> **NCT02171741** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 31 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02171741
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171741, "Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02171741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*